Celiac disease (CD) and irritable bowel syndrome (IBS) share similar symptoms, leading to confusion between the two and diagnostic delay. International guidelines recommend screening individuals with IBS for CD, via serological testing. However, studies published recently have cast doubt on the utility of this. We updated a previous meta-analysis examining this issue.
INTRODUCTION
Irritable bowel syndrome (IBS) is a common symptom-based condition, characterized by abdominal pain in association with alterations in bowel habits ( 1 ) . Th e pathogenesis of IBS is incompletely understood, but abnormalities of motility, visceral sensation, brain-gut interactions, gut microbiome, and mucosal immune function and permeability have been identifi ed (2) (3) (4) (5) (6) . Estimates of prevalence vary between studies, and according to the criteria used for diagnosis, but it is generally believed to aff ect somewhere between 10 and 25% of the general population globally ( 7 ) . Although IBS is not a diagnosis of exclusion, with physicians advised to minimize the use of investigations ( 8, 9 ) , the gastrointestinal (GI) tract has a limited repertoire of symptoms, meaning that abdominal pain and a change in bowel habit is not specifi c to the disorder ( 10 ) .
In contrast, celiac disease (CD) is a well-defi ned immunemediated organic enteropathy, triggered by exposure to gluten in genetically susceptible individuals ( 11 ) , which results in structural Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis damage to the small-intestinal mucosa and may lead to malabsorption. In studies conducted in US and Europe the prevalence of CD is estimated to be between 0.3 and 1% (12) (13) (14) (15) . Th e presenting features of CD are variable, but there is considerable overlap with IBS-type symptoms including abdominal pain, bloating, and change in bowel habit ( 16, 17 ) . Th ese symptoms may be overlooked, leading to mislabeling as IBS, and a delay until the diagnosis of CD is established ( 18 ) .
Although IBS and CD can share similar symptoms, it is imperative to diff erentiate between the two conditions, as their management is diff erent, and CD carries with it the risk of other long-term sequelae if a gluten-free diet is not implemented. In 2009 we published a meta-analysis examining the yield of various diagnostic tests for CD in patients meeting diagnostic criteria for IBS, and showed among those with symptoms suggestive of IBS, the prevalence of biopsy-proven CD was fourfold that of controls without such symptoms ( 19 ) . Economic modeling studies have suggested that excluding CD in patients with symptoms compatible with IBS could be cost-eff ective (20) (21) (22) . Partly as a result of these studies, current guidelines for the management of CD recommend opportunistic screening of patients with IBS-type symptoms for CD, via serological testing ( 23, 24 ) .
However, several high-profi le studies that have been published since the conduct of this meta-analysis have suggested that opportunistic screening for CD in people reporting GI symptoms, or IBS-type symptoms, is not a worthwhile exercise. Two populationbased studies from US reported that a positive serological test for CD was not strongly associated with GI symptoms or IBS ( 12, 25 ) , although the manifestations of CD are protean, and patients may present in a variety of ways, meaning that not all will report GI symptoms. However, a third US study conducted in a referral population reported that the prevalence of positive celiac serology and biopsy-proven CD was similar in non-constipated IBS patients and non-IBS controls ( 26 ) . In light of this, we aimed to update our previous meta-analysis in order to re-appraise the evidence for the role of screening for CD among people with symptoms compatible with IBS.
METHODS

Search Strategy and Study Selection
A thorough literature search was conducted using MEDLINE (1950 to May 2016), EMBASE, and EMBASE Classic (1980 to May 2016). Cross-sectional surveys recruiting unselected adult subjects meeting diagnostic criteria for IBS, with or without healthy controls who did not report symptoms compatible with IBS, and that applied serological tests for CD to all enrolled individuals were eligible for inclusion. Diagnostic criteria for IBS included a physician's opinion, questionnaire data, or specifi c symptom-based criteria, including the Manning ( 27 ) and Rome criteria (28) (29) (30) , or the Kruis scoring system ( 31 ) . Th ese could be supplemented by results of GI investigations, if individual studies performed these. We considered IgA-class antigliadin (AGAs), endomysial (EMAs), or tissue transglutaminase (tTG) antibodies as valid serological markers of possible CD. It was not compulsory for studies to perform distal duodenal biopsy to confi rm CD in individuals with positive serological tests in order to be eligible for inclusion, although we also extracted these data, where reported. Owing to a priori concerns about statistical handling of rare events, studies were only eligible for inclusion if they contained ≥90 individuals. Detailed eligibility criteria for study inclusion are provided in Box 1 .
Studies relating to IBS were identifi ed with the following medical subject headings and free text terms: "irritable bowel syndrome, spastic colon, irritable colon, functional adj5 bowel, Manning, Rome 1, Rome I, Rome 2, Rome II, Rome 3, or Rome III". Th ese were combined together using the "OR" set operator. We then combined these using the set operator "AND" with studies identifi ed using the following terms: "coeliac, celiac, sprue, gluten sensitive enteropathy, villous atrophy, antigliadin, endomyseal, tissue transglutaminase, or duodenal biopsy". Th ere were no language restrictions, and abstracts of the papers identifi ed were assessed for appropriateness to the study question. Th e bibliographies of all identifi ed relevant studies were used to perform a recursive search of the literature. All potentially relevant papers were obtained and evaluated in detail by two reviewers, using predesigned eligibility forms, with all disagreements resolved by consensus.
Data Extraction
Data were extracted from identifi ed papers independently by two reviewers and inputted into a spreadsheet (Microsoft Excel 2010, Microsoft , Redmond, WA), again with discrepancies resolved by consensus. For each eligible study, the following data were extracted: year of publication, country, setting, number of centers, criteria used to defi ne IBS, whether recruited subjects were consecutive, and whether the study design was prospective. Th e proportion of individuals meeting diagnostic criteria for IBS, as well as healthy controls without IBS (where recruited), who were found to have positive celiac serology or biopsy-proven CD was calculated as a percentage of the total number of IBS patients or controls. Where data were incomplete for individual studies, the lead author was contacted in all cases in an attempt to obtain the information of interest.
For cross-sectional surveys that reported the prevalence of a positive test for CD in both individuals meeting criteria for IBS, and healthy controls without IBS, study quality was assessed
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independently by two reviewers using the Newcastle-Ottawa scale ( 32 ) , which judges quality based on the selection of the study groups, the comparability of the groups, and the ascertainment of the outcome of interest. For cross-sectional surveys that only recruited individuals with suspected IBS there are no formal recommended methods for assessing study quality.
Data Synthesis and Analysis
Th e degree of agreement between the two investigators, in terms of judging study eligibility, was measured using the Kappa statistic. Th e proportion of individuals meeting diagnostic criteria for IBS with either a positive serological test, or biopsy-proven CD, were combined for all cross-sectional surveys to give a pooled prevalence in these individuals. In addition, for cross-sectional surveys that also recruited healthy controls without IBS, data were pooled for both cases and controls, and the prevalence of positive celiac serology and biopsy-proven CD were compared between the two groups with an odds ratio (OR) with a 95% confi dence interval (CI). Given the fi ndings from recently published studies ( 12, 25, 26 ) , we conducted sensitivity analyses according to study setting (population-based vs. referral population), geographical region, and IBS subtype (diarrhea predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), and mixed stool pattern IBS (IBS-M)) in order to examine whether this had any eff ect on the prevalence or odds of either positive celiac serology or biopsyproven CD.
Heterogeneity between studies was assessed using the I 2 -statistic with a cut-off of 50%, and the χ 2 -test with a P value of <0.10 used to defi ne a statistically signifi cant degree of heterogeneity ( 33 ) . Data were pooled using a random-eff ects model ( 34 ) , to give a more conservative estimate of the prevalence of a positive serological test for CD, or biopsy-proven CD, in individuals with IBS-type symptoms. Review Manager version 5.3.5 (RevMan for Windows 2014, the Nordic Cochrane Centre, Copenhagen, Denmark) and Stats-Direct version 2.7.7 (StatsDirect Ltd, Sale, Cheshire, UK) were used to generate Forest plots of pooled prevalences and pooled ORs with 95% CIs. Evidence of publication bias was assessed for by applying Egger's test to funnel plots of pooled ORs ( 35 ) , where a suffi cient number of studies (≥10) were available ( 36 ) .
RESULTS
Th e literature search identifi ed 8,360 published citations, of which 50 appeared to be relevant to the study question ( Figure 1 ). Following eligibility assessment, 36 were deemed to be relevant and included in the fi nal analysis, with good agreement between investigators ( κ =0.65). In all, 22 of these studies, including 10,742 individuals, of whom 6,869 met diagnostic criteria for IBS, were published subsequent to our previous meta-analysis studying this issue ( 25, . A further study we identifi ed was a fully published version of an abstract identifi ed and included in the previous meta-analysis. We therefore included data from the fully published paper ( 26 ) , in lieu of the abstract data ( 58 ) . Th ere were another 4,514 subjects identifi ed in 14 studies ( 16, 17, 26, (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) from the previous meta-analysis, of whom 2,406 met diagnostic criteria for IBS. In total, therefore, the 36 studies recruited 15,256 individuals, of whom 9,275 (60.8%) met diagnostic criteria for IBS. Detailed characteristics of all identifi ed studies are provided in Table 1 .
Yield of IgA-class AGA Testing in Suspected IBS
Of the 36 identifi ed studies, 10 reported data on IgA-class AGAs in 4,524 subjects, of whom 2,094 had IBS. Seven of these studies were identifi ed in the previous literature search ( 16, 17, 26, 60, 61, 63, 69 ) , with the remaining three studies identifi ed in the updated search ( 37, 55, 57 ) . Th e pooled prevalence of a positive IgA-class AGA in IBS subjects was 5.7% (95% CI 1.7-11.8%; Table 2 ), but with signifi cant heterogeneity between studies ( I 2 =95.9%, P <0.001). Of these 10 studies, 7 also reported prevalence of a positive IgAclass AGA in non-IBS subjects ( 16, 17, 26, 57, 60, 63, 69 ) . Overall, there were 50 (3.3%) of 1,530 individuals with symptoms compatible with IBS with a positive IgA-class AGA, compared with 26 (1.1%) of 2,430 healthy controls without IBS. Th e OR for a positive IgA-class AGA was signifi cantly higher among those with IBS-type symptoms (3.21; 95% CI 1.55-6.65; Figure 2 and Table 2 ), but with borderline heterogeneity between studies ( I 2 =41.0%, P =0.11). Th ere were too few studies to assess publication bias.
Two studies examined screening for CD with IgA-class AGAs in a population-based setting ( 17, 60 ) . Th ese studies compared 173 Irvine et al. Irvine et al.
Yield of EMA and/or tTG Testing in Suspected IBS
A total of 32 studies reported data on EMA and/or tTG antibodies in 14,150 subjects of whom 8,219 met diagnostic criteria for IBS. In all, 13 of these studies were identifi ed in the previous literature search ( 16, 17, 26, (59) (60) (61) (63) (64) (65) (66) (67) (68) (69) , with the remaining 19 studies identifi ed in the updated search ( 25, (37) (38) (39) (40) (41) (42) (44) (45) (46) (47) (48) 50, 51, (53) (54) (55) (56) (57) . Th e pooled prevalence of a positive EMA and/or tTG was 2.6% (95% CI 1.6-3.8%; Table 2 ), but with signifi cant heterogeneity between studies ( I 2 =89.5%, P <0.001). When studies using EMA or tTG were separated, the prevalence of a positive EMA was 1.1% (95% CI 0.4-2.3%), compared with 3.1% (95% CI 1.8-4.6%) for tTG.
In all, 12 of these 32 studies also reported prevalence of a positive EMA and/or tTG in non-IBS subjects ( 16, 17, 25, 26, 41, 45, 56, 57, 60, 63, 65, 69 ) . Among 2,677 cases with IBS-type symptoms, 57 (2.1%) had a positive EMA and/or tTG, compared with 49 (0.8%) of 5,931 controls. Th e OR for a positive EMA and/or tTG in those with suspected IBS, compared with non-IBS controls was 2.75 (95% CI subjects who met diagnostic criteria for IBS, with 1,127 subjects who served as controls, with a pooled OR for a positive IgAclass AGA of 3.89 (95% CI 1.06-14.3; Figure 2 and Table 2 ). Th e remaining fi ve studies were conducted in secondary-or tertiary-care settings ( 16, 26, 57, 63, 69 ) . Th e OR for a positive IgAclass AGA in 1,357 cases with suspected IBS vs. 1,303 controls was 2.87 (95% CI 1.07-7.66; Figure 2 and Table 2 ). Only one of these studies was conducted in North America, and the prevalence of a positive IgA-class AGA was not higher among subjects meeting criteria for IBS ( 26 ) . In contrast, there were three European studies, and the OR for a positive IgA-class AGA was signifi cantly higher among those with IBS-type symptoms (4.38; 95% CI 1.74-11.0; Figure 2 and Table 2 ) ( 16, 17, 60 ) . When prevalence of a positive IgA-class AGA was examined according to IBS subtype, this was highest in those meeting criteria for IBS-M, but the odds of a positive IgA-class AGA was only signifi cantly higher among those with IBS-D (OR 17.1; 95% CI 4.77-61.1; Table 3 ). Figure 3 and Table 2 ), and no signifi cant heterogeneity between studies ( I 2 =31.0%, P =0.17). When EMA and tTG were considered separately, the OR for a positive EMA in cases with IBS compared with controls was 3.92 (95% CI 1.32-11.7), and that for a positive tTG was 3.02 (95% CI 1.44-6.36). Th ere was no evidence of funnel plot asymmetry to suggest publication bias or other small study eff ects (Egger's test, P =0.28).
A total of 4 of the 12 studies were population-based ( 17,25,60,65 ) comparing 657 cases meeting diagnostic criteria for IBS with 3,967 controls. Th e OR for a positive EMA and/or tTG in subjects with suspected IBS, compared with healthy controls was 1.01 (95% CI 0.20-5.09; Figure 3 and Table 2 ). Th e remaining eight studies were conducted in secondary-or tertiary care ( 16, 26, 41, 45, 56, 57, 63, 69 ) . Th e OR for a positive EMA and/or tTG in 2,020 individuals meeting criteria for IBS, compared with 1,964 controls, was 4.32 (95% CI 2.17-8.58; Figure 3 and Table 2 ). Th ree of these studies were conducted in North America, and the prevalence of a positive EMA and/or tTG was no higher among subjects meeting criteria for IBS ( 25, 26, 65 ) . Again, there were three European studies, and the OR for a positive EMA and/or tTG was signifi cantly higher among those with IBS-type symptoms (4.05; 95% CI 1.36-12.1; Table 2 ) ( 16, 17, 60 ) . When prevalence of a positive EMA and/or tTG was examined according to IBS subtype, this was highest in those meeting criteria for IBS-D. Th e odds of a positive EMA and/or tTG was signifi cantly higher among those with IBS-D (OR 6.09; 95% CI 1.88-19.7) and IBS-C (OR 4.84; 95% CI 1.32-17.7; Table 3 ).
Yield of Duodenal Biopsy after Positive Celiac Serology
Th ere were 22 studies that off ered duodenal biopsy to individuals with a positive serological test for CD of any type. Seven of these studies were identifi ed in the previous literature search ( 16, 17, 26, 62, 63, 68, 69 ) . Th e remaining 15 studies were identifi ed in the updated search ( 37, 39, 40, 43, 44, (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) . Th ese studies contained 9,784 subjects, of whom 6,991 met diagnostic criteria for IBS. Th e pooled prevalence of biopsy-proven CD in these studies was 3.3% (95% CI 2.3-4.5%; Table 2 ), but with signifi cant heterogeneity between study results ( I 2 =84.6%, P <0.001). Of the 22 studies, 8 recruited 2,025 subjects with IBS-type symptoms and 2,793 healthy controls without ( 16, 17, 26, 49, 56, 57, 63, 69 ) . Overall, there were 49 (2.4%) individuals meeting criteria for IBS with duodenal biopsy fi ndings consistent with CD, compared with 16 (0.6%) subjects who did not meet criteria for IBS, with an OR of 4.48 (95% CI 2.33-8.60; Figure 4 and Table 2 ), and no signifi cant heterogeneity between studies ( I 2 =0%, P =0.45). Th ere were too few studies to assess for publication bias.
Only one of these studies was population-based ( 17 ), and compared 123 cases meeting diagnostic criteria for IBS with 1,077 controls. Th e OR for a duodenal biopsy consistent with CD in IBS cases compared with controls was 4.49 (95% CI 1.33-15.1; Figure  4 and Table 2 ). Th e remaining seven studies were based in secondary-or tertiary-care settings ( 16, 26, 49, 56, 57, 63, 69 ) , and contained 1,902 IBS cases and 1,716 controls, with an OR for biopsyproven CD of 4.46 (95% CI 1.88-10.6; Figure 4 and Table 2 ). Only the study by Cash et al. ( 26 ) was conducted in North America, and the prevalence of a biopsy-proven CD was no higher among subjects meeting criteria for IBS. Again, there were three European studies, and the OR for biopsy-proven CD was signifi cantly higher among those with IBS-type symptoms (5.45; 95% CI 2.13-14.0; Irvine et al.
CD, in the form of a gluten-free diet, and important long-term consequences from non-treatment including increased rates of lymphoma, infertility, anemia, and osteoporosis. Given all this, clinicians should continue to pursue the diagnosis of CD aggressively in patients with suspected IBS, acknowledging that around 30 people will need to be tested to diagnose one new case of biopsy-proven CD. Th e prevalence of both IBS and CD vary, depending on ethnicity and geographical location ( 7, (70) (71) (72) , likely refl ecting the diff erences in diet, genetics, and culture. Th is meta-analysis included studies from multiple countries, recruiting patients of diff erent ethnic origins. Th is is a potential strength, in that it increases the generalizability of the fi ndings to patients consulting with symptoms compatible with IBS in diff erent countries, but is also a weakness in that the pooled results from the metaanalysis may not be applicable to all patient groups. Nine of the 37 included studies, which recruited 3,122 of the 15,256 subjects in the meta-analysis, were conducted in Iranian populations ( 38, 41, 44, 45, 47, 51, 53, 54, 63 ) . Having such a large proportion of the included subjects from one geographical location and ethnicity has the potential to skew the results, and in our subgroup analyses, according to geographic location of the study, the OR for biopsy-proven CD in studies conducted in the Middle East appeared substantially larger than that derived from studies conducted in Europe or North America.
Other limitations of this meta-analysis include heterogeneity in some of our analyses when data from individual studies were pooled, and the fact that we did not conduct a search of the gray literature in order to identify unpublished studies. In addition, this was highest in those meeting criteria for IBS-D. Th e odds of biopsy-proven CD were signifi cantly increased across all subtypes of IBS, but were highest among those with IBS-D (OR 12.4; 95% CI 4.98-30.9; Table 3 ).
DISCUSSION
Th e results of this updated systematic review and meta-analysis demonstrate that the pooled prevalence of a positive serological test for CD in individuals with suspected IBS is between 2.6 and 5.7%, and the OR for a positive test was up to threefold higher among those meeting criteria for IBS. Th e pooled prevalence of biopsy-proven CD was similar, at 3.3%, and again this was signifi cantly more common in those with IBS-type symptoms, with an OR of almost 4.5. However, in some of our analyses when only North American studies-or when only studies conducted in the general population-were considered, the odds of a positive serological test for CD and of biopsy-proven CD, were no longer signifi cantly greater. Th is suggests that the utility of screening for CD among individuals reporting, or presenting with, symptoms compatible with IBS in these settings is less clear. Only one study reported data on biopsy-proven CD in a population-based setting ( 17 ) , and although the OR was signifi cantly higher in those with presumed IBS, compared with controls, this fi nding should be interpreted with caution. Although the OR for a positive serological test for CD was not consistently elevated across all IBS subtypes, the OR for biopsy-proven CD was signifi cantly higher for IBS-D, -C, and -M, vs. controls without symptoms meeting criteria for IBS. Th ere is a highly eff ective treatment for 
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there is the possibility that the prevalence of a positive serological test for CD has been infl ated, due to false-positive test results. However, the specifi city of these tests for a diagnosis of CD is around 95% ( 73 ), and we still observed rates of biopsy-proven CD in excess of 3% among those with symptoms suggestive of IBS, more than fourfold those of individuals who did not meet criteria for IBS. In addition, it is equally plausible that the rate of biopsy-proven CD has been underestimated in this metaanalysis. Th e sensitivity of these tests is 88-93% ( 73 ) and, in the majority of studies, distal duodenal biopsy was not performed in those with a negative test, meaning that a diagnosis of CD will have been missed in those with a false-negative result. Th is issue may have been further compounded by the fact that not all patients with a positive serological test agreed to undergo upper GI endoscopy and biopsy. Th e quality of any meta-analysis relies on the quality of the included studies, leading many authors to utilize validated assessment tools to assess study quality. We applied the Newcastle-Ottawa scale ( 32 ) , which is used to assess the quality of casecontrol studies, to cross-sectional surveys that recruited subjects with symptoms meeting criteria for IBS as well as healthy controls without IBS-type symptoms. Six of these 13 studies scored 7 or more out of a possible 9 on the scale. With respect to other measures of the rigor of individual study design, 28 studies stated specifi cally that they were prospective, and 16 that they recruited consecutive patients. In addition, almost all used validated criteria for the diagnosis of IBS, with 27 using the Rome II or Rome III criteria, and one using the Manning criteria.
Internationally, guidelines suggest that tTG antibody testing (±EMA testing) should be used over AGAs for the diagnosis of CD ( 23, 24 ) , due to the higher sensitivity and specifi city of these tests ( 74 ) , and that opportunistic screening of individuals with IBS using these serological tests for CD should be considered ( 23, 24 ) . As such, if we focus on the data from studies that used EMA and/or tTG in this meta-analysis, overall, the results support screening for CD in patients presenting to secondary or tertiary care. However, a benefi t of screening people at either a population level, or within primary care, is not supported by our results. It is important to point out that there were fewer studies in these analyses, and more data are probably required in order to judge the utility of screening in both of these settings, particularly as primary care is where the majority of patients with IBS are managed ( 75 ) . Th e recent evidence casting doubt on the role of CD screening in patients with IBS-type symptoms, and particularly in the community, comes mainly from North American studies ( 12, 25, 26 ) . We conducted a subgroup analysis of data from North America and, although the small number of studies limits the strength of these fi ndings, it showed little difference in CD prevalence, or a positive serological test for CD, between those with symptoms meeting diagnostic criteria for IBS and controls without GI symptoms, even in a secondary-or tertiary-care setting. Irvine et al.
tion of a low FODMAP diet and a gluten-free diet in IBS, there was no additive eff ect of a gluten-free diet ( 78 ) , suggesting that reduced fructans consumption explains the benefi cial eff ect of gluten exclusion in IBS. In addition, a recent pooled analysis of double-blind, placebo-controlled trials of gluten challenge in presumed non-celiac gluten sensitivity demonstrated that only 1 in 6 patients exhibited gluten-specifi c symptoms, and 40% of these individuals also reported an exacerbation of their symptoms with placebo ( 79 ) . Regardless of these issues, it is likely that clinicians will come under increasing pressure from patients to exclude CD, by means of serological testing, irrespective of the likely yield or cost-eff ectiveness of this strategy.
In conclusion, this updated meta-analysis, containing data from a further 22 studies published aft er the previous version ( 19 ) , demonstrates a pooled prevalence of biopsy-proven CD of 3.3% among individuals with IBS-type symptoms, with a more than fourfold odds of CD, compared with healthy controls, and this was consistent across all IBS subtypes. Despite the recent publication of some studies that have cast doubt on the value of screening individuals with symptoms suggestive of IBS for CD, these fi ndings are similar to the previous pooled estimates from our meta-analysis published in 2009. Th ese data, along with those from economic modeling studies, support continued screening of patients with symptoms meeting diagnostic criteria for IBS in secondary and tertiary-care, outside of North America. Th e value of screening individuals with IBS symptoms in the community or in primary care is less clear. Further studies to improve our understanding of the yield and cost-eff ectiveness of screening for CD in these settings are encouraged.
Several studies have shown that testing for CD in patients with IBS-type symptoms is likely to be cost-eff ective (20) (21) (22) . Spiegel et al. ( 21 ) reported that histological testing for CD had an acceptable cost when CD prevalence was >1%, and became the dominant strategy, cheaper than empirical symptom-based therapy for presumed IBS, when the prevalence reached 8%. Another study reported that at a CD prevalence of 3% there was only a 1% increase in lifetime costs of managing IBS with tTG testing for CD, with the cost per quality-adjusted life year falling to $4,900 if the prevalence of CD in IBS was assumed to be 5% ( 20 ) , close to the upper confi dence limit of the estimate from our meta-analysis. Mohseninejad et al. ( 22 ) found testing for CD in patients presenting with non-constipated IBS was almost certainly cost-eff ective at a prevalence of 4.7%, again similar to the upper limit we estimated. It is therefore likely, from the up-to-date synthesis of data in this meta-analysis, that testing for CD remains acceptable in terms of cost, although the prevalence of CD falls slightly short of making serological testing the dominant strategy.
Many patients with IBS believe their symptoms relate to food sensitivity ( 76 ) , and some individuals who have no genetic, serological, or mucosal markers of CD report symptom improvement following withdrawal of gluten from their diet ( 77 ), a phenomenon referred to as non-celiac gluten sensitivity. However, the existence of this entity is not without controversy. As wheat also contains high levels of fructans, in addition to gluten, another explanation for the benefi t of gluten withdrawal in patients with IBS could be a simultaneous reduction in fructans, which is one of the FODMAPs (fermentable oligo-, di-, or monosaccharides and polyols). In a recent trial examining a combina- Figure 4 . Pooled odds ratio for biopsy-proven celiac disease in cases with IBS-type symptoms compared with controls without IBS-type symptoms.
